表紙
市場調査レポート

アテローム性動脈硬化症:世界の治験レビュー

Atherosclerosis Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 311438
出版日 ページ情報 英文 127 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
アテローム性動脈硬化症:世界の治験レビュー Atherosclerosis Global Clinical Trials Review, H2, 2014
出版日: 2014年08月25日 ページ情報: 英文 127 Pages
概要

当レポートでは、アテローム性動脈硬化症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、概略以下の構成でお届けします。

イントロダクション

  • アテローム性動脈硬化症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:心血管関連の治験におけるアテローム性動脈硬化症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:心血管関連の治験におけるアテローム性動脈硬化症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数 アテローム性動脈硬化症

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

アテローム性動脈硬化症治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース アテローム性動脈硬化症

治験のプロファイル

  • 主要企業の治験の概要
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • 第一三共
    • Sanofi
  • 代表的な研究機関・病院の治験の概要
    • National Heart, Lung, and Blood Institute
    • Korea University
    • Brigham and Women's Hospital
    • Mayo Clinic
    • National Institute on Aging
    • Tehran University of Medical Sciences
    • National Defense Medical College
    • University of California, San Francisco
    • Johns Hopkins University
    • National Taiwan University Hospital

5つの代表的な治験のプロファイル

付録

目次

GlobalData's clinical trial report, "Atherosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Atherosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atherosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Atherosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Atherosclerosis
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Atherosclerosis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Atherosclerosis Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Atherosclerosis
    • Jul 30, 2014: AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Daiichi Sankyo Company, Limited
      • Clinical Trial Overview of Daiichi Sankyo Company, Limited
      • Sanofi
      • Clinical Trial Overview of Sanofi
    • Clinical Trial Overview of Top Institutes / Government
      • National Heart, Lung, and Blood Institute
      • Clinical Trial Overview of National Heart, Lung, and Blood Institute
      • Korea University
      • Clinical Trial Overview of Korea University
      • Brigham and Women's Hospital
      • Clinical Trial Overview of Brigham and Women's Hospital
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • National Institute on Aging
      • Clinical Trial Overview of National Institute on Aging
      • Tehran University of Medical Sciences
      • Clinical Trial Overview of Tehran University of Medical Sciences
      • National Defense Medical College
      • Clinical Trial Overview of National Defense Medical College
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Johns Hopkins University
      • Clinical Trial Overview of Johns Hopkins University
      • National Taiwan University Hospital
      • Clinical Trial Overview of National Taiwan University Hospital
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Atherosclerosis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Atherosclerosis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Atherosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Atherosclerosis Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Korea University, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Brigham and Women's Hospital, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Aging, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Defense Medical College, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014*
  • Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014*

List of Figures

  • Atherosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014*
  • Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014*
  • Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top